Status:
COMPLETED
Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
Lead Sponsor:
Xiaofan Zhu
Conditions:
Leukemia
Eligibility:
All Genders
1-14 years
Phase:
PHASE4
Brief Summary
Several groups, especially the PETHEMA group (in their LPA96 and 99 trials), obtained low relapse rates in newly diagnosed Acute Promyelocytic Leukemia (APL) patients by combining ll-transretinoic aci...
Detailed Description
Some studies suggest patients with high-risk disease should be treated with intensified doses of anthracycline, or intermediate/ high-dose Ara-C or As2O3 as an early consolidation, so as to decrease t...
Eligibility Criteria
Inclusion
- Acute Promyelocytic Leukemia (APL)
Exclusion
- \> 14
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2017
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT01191541
Start Date
May 1 2010
End Date
February 1 2017
Last Update
August 10 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China, 300020
2
Department of Pediatrics, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, PR China
Tianjin, China, 300020